# Core Diagnostics Private

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/core-diagnostics-private

- Industry: Healthcare
- Headquarters: Gurgaon, India
- Website: www.corediagnostics.in
- Total disclosed funding: $12M
- Latest round: Series B (Dec 2, 2016)
- Investors on record: 3

## About

Core Diagnostics Private Limited, based in India, specializes in advanced diagnostic solutions, focusing on oncology, reproductive health, and genetic disorders. Through cutting-edge technology, they provide precise diagnostic testing to healthcare providers and patients alike.Core Diagnostics Private Limited is focused on delivering advanced diagnostics. The company was founded in 2012 and is headquartered in Gurgaon, India. It has received a total of 3 funding rounds, with the latest being an Add-on, Trade Sale in December 2024, where Metropolis Healthcare Limited acquired the company for INR 2.46 billion, funded partly in cash and partly through an equity swap. The CEO of the company is Mohan Uttarwar. Overall, Core Diagnostics has raised a total of INR 12.00 mn in funding.Core Diagnostics specializes in advanced diagnostic solutions that address a wide array of medical conditions, particularly in oncology, reproductive health, cardiovascular diseases, genetic disorders, and urological and ophthalmologic conditions. Their core product offerings include high-end molecular testing techniques such as liquid biopsies, PCR, and next-generation sequencing, alongside comprehensive cytopathology and histopathology services. These diagnostic tools are designed to provide precise answers for hereditary and sporadic cancers, multiple hematological disorders, infertility, and chronic diseases like kidney and cardiovascular disorders. Core Diagnostics serves a diverse client base, including healthcare providers, hospitals, and clinics across various regions, with a notable presence in India and partnerships in international markets.Core Diagnostics generated revenue of INR 11,442,694.80 in the most recent year, 2023. The company's EBITDA for the same year was INR -1,181,894.60. Revenue is primarily derived from diagnostic services structured around a fee-for-service model, serving both direct-to-consumer clients and B2B arrangements with healthcare facilities.In December 2024, Metropolis Healthcare Limited, a portfolio company of several investment firms, agreed to fully acquire Core Diagnostics Private Limited. This acquisition aims to expand Metropolis Healthcare's resources for advanced cancer testing and broaden its market reach. The strategic use of resources post-acquisition will enhance the company's capacity to develop new diagnostic products and extend its presence into new markets.

## Funding rounds

- Series B, Dec 2, 2016, $12M — Artiman Ventures, Eight Roads Ventures, F-Prime Capital

## Investors

- Artiman Ventures (https://capitalatlas.ai/funds/artiman-ventures) — Series B
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B